ClinicalTrials.gg
Sign In
Status unknownNCT03359135VECOUpdated Feb 28, 2018

Compression Garments on Hypermobility Type of Ehlers-Danlos Syndrome (CGhEDS)

An observational study in Hypermobility Type Ehlers-Danlos Syndrome, sponsored by Hôpital Raymond Poincaré. Status unknown at 1 site in France. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-02-28.

Sponsored by Hôpital Raymond Poincaré · Observational

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
16 Years and older
Sex
All
01

Study summary

This study evaluates the effects of wearing a compression garment on the postural balance of patients with hypermobility type of Ehlers-Danlos syndrome, in randomised controlled study.

02

Conditions studied

  • Hypermobility Type Ehlers-Danlos Syndrome

Keywords

  • Compression garment
03

In context

Ehlers-Danlos syndrome type 3

28 studies on the registry are indexed under Ehlers-Danlos syndrome type 3; 9 are open to participants now.

This study's planned enrollment of 40 is close to the median of 39 across 12 observational studies indexed under Ehlers-Danlos syndrome type 3.

Browse Ehlers-Danlos syndrome type 3 studies →

Lead sponsor

Hôpital Raymond Poincaré is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

hypermobility type of Ehlers-Danlos syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥16 years
  • hEDS with the 2017 diagnostic criteria .
  • A normal neurological examination with no sensory disorders, no cerebellar syndrome or vestibular syndrome.
  • An optimal balanced analgesic treatment before inclusion
  • Patients who have not modified their physical treatment (physiotherapy) since 6 months.

Exclusion criteria

Exclusion Criteria:

  • Surgery of the lower limb (hip, knee or ankle)
  • Patient having already wear compression garments in the year preceding.
  • Neurological history of sensory , vestibular or cerebellar disorders.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • group1

    hEDS treated with rehabilitation only

    Other: Rehabilitation

  • group 2

    hEDS treated with rehabilitation associated to compression garments wearing

    Other: Rehabilitation · Device: Compression Garment

Interventions

  • OtherRehabilitation

    Rehabilitation during 4 weeks

  • DeviceCompression Garment

    Rehabilitation associated to wearing CG during 4 weeks

06

What researchers measure

Primary outcomes

  1. Centre of pression speed

    a stability parameter on a force plate

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2018; primary completion for Oct 2018, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2017
First posted
Dec 2, 2017
StartEst.
Apr 1, 2018
Primary completionEst.
Oct 2018
CompletionEst.
Apr 2019
Last update
Feb 28, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03359135
Lead sponsor
Hôpital Raymond Poincaré
Responsible party
Sponsor
First posted
Dec 2, 2017
Start date
Apr 1, 2018 (estimated)
Primary completion
Oct 2018 (estimated)
Completion
Apr 2019 (estimated)
Last update
Feb 28, 2018

Study contacts

BENISTAN Karelle, Dr
Contact
karelle.benistan@aphp.fr
0033147104440
GADER Nadra, Dr
Contact
nadra.gd@gmail.com
0033788127902

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Ehlers-Danlos syndrome type 3 →

Other studies from this sponsor

Hôpital Raymond Poincaré

Start the discussion